Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05178303 · ClinicalTrials.gov registry record · Phase 4

Composition for Treating Cirrhosis and Liver Cancer (SB-1121)

A Phase 4 study of Cirrhosis of the Liver, sponsored by Nguyen Thi Trieu, MD.

Completed
Registry status
Phase 4
Development phase
134
Enrollment target
2
Study locations

NCT05178303 is a Phase 4 study of Cirrhosis of the Liver that has completed, run by Nguyen Thi Trieu, MD. The registered enrollment target is 134 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05178303, a Phase 4 study of Cirrhosis of the Liver, has completed, sponsored by Nguyen Thi Trieu, MD.

COMPLETED
Registry status
Phase 4
Development phase
134 participants
Enrollment target
2
Study locations

Study Summary

The composition treats cirrhosis and hepatocellular carcinoma (Hcc) at an early stage. The product is extracted from herbs, including Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Ascorbic acid, pyridoxine 5-phosphate, L-Arginine hydrochloride, Pregnenolone acetate. These components have participated in repairing and regenerating new liver parenchyma, preventing fibrosis cell generation, preventing liver cancer cell growth at an early stage. The composition supplements precursors which help the body strengthen antibodies and reduce the risk of inflammation, restore physiological and biochemical functions of liver cells after chronic inflammation.

Conditions Studied

Interventions

  • DRUG SB-1121(1)
  • DRUG SB-1121(2)

Study Locations (2)

Delaware

  • Saigon Biopharma LLC - Wilmington

Other

  • Saigon Biopharma Company Limited - Ho Chi Minh City

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2015-11-30
Est. Completion 2021-11-10
Phase Phase 4

Sponsor

Nguyen Thi Trieu, MD

2 total trials

What the Registry Record Tells You About NCT05178303

The ClinicalTrials.gov registry entry for NCT05178303 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nguyen Thi Trieu, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cirrhosis of the Liver appearing as the primary indexed condition, and to 2 interventions - of which SB-1121(1) is the first listed.

NCT05178303 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Delaware, Other.

Frequently Asked Questions

What is clinical trial NCT05178303 about?

NCT05178303 is a clinical study titled "Composition for Treating Cirrhosis and Liver Cancer (SB-1121)". The composition treats cirrhosis and hepatocellular carcinoma (Hcc) at an early stage. The product is extracted from herbs, including Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Ascorbic acid, pyridoxine 5-phosphate, L-Arginine h...

What is the current status of trial NCT05178303?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2015-11-30. Estimated completion is 2021-11-10.

What conditions does trial NCT05178303 study?

This clinical trial studies the following conditions: Cirrhosis of the Liver.

What interventions are being tested in trial NCT05178303?

The interventions under investigation include: SB-1121(1) (DRUG), SB-1121(2) (DRUG).

Who is sponsoring clinical trial NCT05178303?

This trial is sponsored by Nguyen Thi Trieu, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05178303 being conducted?

This trial has 2 study locations across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.